The ISBT Resources Library offers a rich variety of documents, publications, e-learning material and external links. Please use the filters to narrow your search results by information type, topic or publication year.
The page lists all official FDA Guidance Documents and other regulatory guidance. You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.
The Circular of Information (the Circular) is made available through the important work of the AABB's Circular of Information Task Force. This webpage provides the background information for compliance with FDA requirements under 21 CFR 606.122 for use of the Circular, including information on purchase options, implementation, and updated language. AABB encourages you to review the information for important changes.
Blood and blood components are biological products, and in the form of cellular products are living human tissue intended for use in the treatment of patients
BSH site with a wide range of guidelines, position papers and good practice papers on clinical and laboratory aspects of transfusion, haematology and haemostasis.
Multiple barriers to the safety and availability of blood components for transfusion were identified in the 2015 Global Database on Blood Safety, many of which derive from weak regulatory oversight, insufficient financing, and fragmentation of the national blood system. Centralization of key functions of the blood service within a limited number of blood establishments, particularly testing and processing of blood donations, can overcome several shortcomings that often exist in decentralized blood systems that are highly fragmented.
This guidance document has been produced by WHO to assist blood services in the development of national plans to respond to any emerging infectious threats to the sufficiency or safety of the blood supply, whether from an existing infectious agent that is changing in incidence and spread, or from a newly identified infectious agent.
